JESSE CABILING: Open Payments
NPI 1790443521 · HASBROUCK HEIGHTS, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$609 in 25 payments from 14 companies in 2025. Trend: 2023 $484 · 2024 $424 · 2025 $609
Food & beverage: $609
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 5 | $130 |
| Alexion Pharmaceuticals, Inc. | 4 | $89 |
| Merck Sharp & Dohme LLC | 3 | $71 |
| TerSera Therapeutics LLC | 2 | $65 |
| Stemline Therapeutics Inc. | 2 | $46 |
| SOBI, INC | 1 | $36 |
| Ipsen Biopharmaceuticals, Inc | 1 | $26 |
| Eisai Inc. | 1 | $24 |
| Melinta Therapeutics, LLC | 1 | $24 |
| Astellas Pharma US Inc | 1 | $24 |
Products named: Fabhalta, ULTOMIRIS, KEYTRUDA, Xermelo, Orserdu, Vonjo, Onivyde, Lenvima.
Industry payments across NJ — which companies pay providers there.
